S, H., M, M., D, O., A, S., E, B., & E, H. (2019). Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: A population-based modelling study. Expert review of pharmacoeconomics & outcomes research, 19(2), 223. https://doi.org/10.1080/14737167.2019.1522501
Chicago Style (17th ed.) CitationS, Himmler, Müller M, Ostwald D, Seddik A, Basic E, and Hradetzky E. "Long-term Health Benefits of Stroke Prevention with Apixaban Versus Vitamin K Antagonist Warfarin in Patients with Non-valvular Atrial Fibrillation in Germany: A Population-based Modelling Study." Expert Review of Pharmacoeconomics & Outcomes Research 19, no. 2 (2019): 223. https://doi.org/10.1080/14737167.2019.1522501.
MLA (9th ed.) CitationS, Himmler, et al. "Long-term Health Benefits of Stroke Prevention with Apixaban Versus Vitamin K Antagonist Warfarin in Patients with Non-valvular Atrial Fibrillation in Germany: A Population-based Modelling Study." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 19, no. 2, 2019, p. 223, https://doi.org/10.1080/14737167.2019.1522501.
